Pediatric Blood and Marrow Transplant Program, Seidman Cancer Center, Cleveland, OH, USA.
Blood. 2012 Feb 23;119(8):1801-9. doi: 10.1182/blood-2011-10-384354. Epub 2012 Jan 6.
Multipotent, bone marrow-derived stromal cells (BMSCs, also known as mesenchymal stem cells [MSCs]), are culture-expanded, nonhematopoietic cells with immunomodulatory effects currently being investigated as novel cellular therapy to prevent and to treat clinical disease associated with aberrant immune response. Emerging preclinical studies suggest that BMSCs may protect against infectious challenge either by direct effects on the pathogen or through indirect effects on the host. BMSCs may reduce pathogen burden by inhibiting growth through soluble factors or by enhancing immune cell antimicrobial function. In the host, BMSCs may attenuate pro-inflammatory cytokine and chemokine induction, reduce pro-inflammatory cell migration into sites of injury and infection, and induce immunoregulatory soluble and cellular factors to preserve organ function. These preclinical studies provide provocative hints into the direction MSC therapeutics may take in the future. Notably, BMSCs appear to function as a critical fulcrum, providing balance by promoting pathogen clearance during the initial inflammatory response while suppressing inflammation to preserve host integrity and facilitate tissue repair. Such exquisite balance in BMSC function appears intrinsically linked to Toll-like receptor signaling and immune crosstalk.
多能骨髓基质细胞(BMSCs,也称为间充质干细胞[MSCs])是经过培养扩增的非造血细胞,具有免疫调节作用,目前正在研究作为新型细胞疗法,以预防和治疗与异常免疫反应相关的临床疾病。新出现的临床前研究表明,BMSCs 可以通过直接作用于病原体或通过间接作用于宿主来保护免受感染挑战。BMSCs 可以通过可溶性因子抑制生长或增强免疫细胞的抗菌功能来减少病原体负担。在宿主中,BMSCs 可以减弱促炎细胞因子和趋化因子的诱导,减少促炎细胞向损伤和感染部位的迁移,并诱导免疫调节性可溶性和细胞因子来维持器官功能。这些临床前研究为 MSC 治疗未来的发展方向提供了有启发性的线索。值得注意的是,BMSCs 似乎作为一个关键的支点,通过在初始炎症反应期间促进病原体清除来提供平衡,同时抑制炎症以维持宿主完整性并促进组织修复。BMSC 功能的这种微妙平衡似乎与 Toll 样受体信号和免疫串扰内在相关。